Abstract
Paliperidone palmitate long-acting injection (Xeplion® aqueous suspension for IM injection, PP) is the long-acting injectable antipsychotic for schizophrenia, which approved in Japan on September 2013. PP is provided as prefilled syringe, which makes enable the injection without preparation just before injection. PP is injected as 150mg at Day 1 and 100mg at Day 8 to deltoid muscles, followed by the injection of 75 mg every 4 week to deltoid or gluteal muscle (appropriately increase or decrease within 25-150mg by depending on the state of patients), indicates the effect on schizophrenia without concomitant oral antipsychotics. In this paper, it is introduced as the characteristics of drug formulation and pharmacokinetics of PP.
